Posts

Posted on

PMI Partners with U.S. Department of Homeland Security on Combatting Illicit Trade

PMI Partners with U.S. Department of Homeland Security on Combatting Illicit Trade

NEW YORK–(BUSINESS WIRE)–
Philip Morris International Inc. (PMI) (NYSE: PM) today signed a memorandum of understanding (MOU) with the National Intellectual Property Rights Coordination Center (IPR Center) at the U.S. Department of Homeland Security (DHS) to assist and support Homeland Security Investigations’ (HSI) illicit tobacco trade operations and other intellectual property rights investigations.

“We are thrilled to partner with DHS and the IPR Center to combat the illicit tobacco trade,” said PMI’s head of illicit trade prevention for the U.S. Hernan Albamonte. “This partnership will provide both parties necessary information to thwart terrorist and criminal organizations that profit from the trade of illicit tobacco and jeopardize our national security.”

The MOU is focused on comprehensive strategies and coordinating efforts to disrupt and combat all forms of illicit tobacco trade, as well as to address vital areas of intellectual property, brand protection, and anti-counterfeiting strategies. The agreement will also facilitate knowledge transfer between the center and PMI to share mutually beneficial information and research to combat the illicit tobacco trade and assist in other intellectual property rights investigations.

“The agreement being signed today, is a continuation of a years-long partnership between the IPR Center and PMI to protect the American public by enforcing the nation’s intellectual property rights laws and educating consumers on the dangers of illicitly traded tobacco products. The IPR Center will leverage this robust public-private partnership to develop outreach, training efforts and share referral information to open investigations and target these criminal acts,” said Steve Francis, IPR Center director.

Following an unprecedented year—when criminal and terrorist organizations swiftly adapted and migrated their operations to suit the new environment—this partnership illustrates how public- and private-sector cooperation can make full use of existing expertise and information sharing to foster innovative solutions and evolving technologies.

In 2020, PMI recognized the urgent need to convene a myriad group of government, diplomatic, public, and private institutions to advance solutions to strengthen national security by upping the fight against illicit products—from illicit tobacco-containing products to faulty personal protective equipment (PPE). These successes include:

  • Taking tens of thousands of online and offline enforcement actions against IP infringements in the U.S. and globally, including against IP infringing online marketplace listings, social media accounts, and websites.
  • Working in close cooperation with state and local law enforcement agencies across the U.S. to disrupt online operations illegally distributing tobacco containing products.
  • Launching a first of its kind, six-week virtual certification course titled “Illicit Trade in Tobacco Products: Convergence with Crime,” comprised of more than 500 registrants representing 133 U.S. law enforcement agencies.
  • Building sustainable public-private partnerships through initiatives such as:
  • PMI IMPACT, a first-of-its-kind global initiative to support public, private, and nongovernmental organizations, which has allocated $48 million for the implementation of more than 60 projects in 30 countries to combat illegal trade and related crimes.
  • Driving more than 346,000 clicks to DHS resources dedicated to helping recognize and report fraudulent PPE goods through a public service campaign—led by PMI and supported by other private industry and academic leaders—to raise awareness about the emerging threat of fraudulent PPE products.

During the signing event at the IPR Center, PMI’s vice president of external affairs J.B. Simko said, “PMI is focused on developing smoke-free alternatives that are a better choice for adults than continued smoking. Our goal is that one day these products will replace combustible cigarettes for good. The illicit trade undermines these efforts by making unregulated products more accessible, so we are determined to do our part to fight it.”

Philip Morris International: Delivering a Smoke-Free Future

Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. In addition, PMI ships a version of its IQOS Platform 1 device and its consumables to Altria Group, Inc. for sale under license in the U.S., where the U.S. Food and Drug Administration (FDA) has authorized their marketing as a modified risk tobacco product (MRTP), finding that an exposure modification order for these products is appropriate to promote the public health. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI’s smoke-free product portfolio includes heat-not-burn and nicotine-containing vapor products. As of Sept. 30, 2020, PMI estimates that approximately 11.7 million adult smokers around the world have already stopped smoking and switched to PMI’s heat-not-burn product, available for sale in 61 markets in key cities or nationwide under the IQOS brand. For more information, please visit www.pmi.com and www.pmiscience.com.

# # #

Sam Dashiell

Philip Morris International Media Office

T. +1 (202) 480 1617

E. [email protected]

KEYWORDS: New York Europe Switzerland United States North America

INDUSTRY KEYWORDS: Professional Services Public Policy/Government Retail Other Professional Services Other Retail Tobacco Homeland Security

MEDIA:

Logo
Logo
Posted on

TMX Group, Wishpond, C-Suite at The Open

Canada NewsWire

TORONTO, Jan. 29, 2021 /CNW/ – Ali Tajskandar, Founder & CEO, Wishpond Technologies Ltd. (TSXV: WISH), shares his company’s story in an interview with TMX Group.

The C-Suite at The Open video interview series highlights the unique perspectives of listed companies on Toronto Stock Exchange and TSX Venture Exchange. Videos provide insight into how company executives think in the current business environment. To see the latest C-Suite at The Open videos visit https://www.tmxmoney.com/en/csuite.html.


About Wishpond Technologies Ltd. (TSXV: WISH)

Wishpond Technologies Ltd. is a marketing platform for managing, generating and nurturing leads. The platform provides social promotions, website popups, online forms, lead activity tracking, lead management, lead intelligence, marketing automation, email marketing and marketing analytics. For more information visit: https://www.wishpond.com/ 


About TMX Group (TSX: X)

TMX Group’s key subsidiaries operate cash and derivative markets and clearinghouses for multiple asset classes including equities and fixed income. Toronto Stock Exchange, TSX Venture Exchange, TSX Alpha Exchange, The Canadian Depository for Securities, Montréal Exchange, Canadian Derivatives Clearing Corporation, Trayport and other TMX Group companies provide listing markets, trading markets, clearing facilities, depository services, technology solutions, data products and other services to the global financial community. TMX Group is headquartered in Toronto and operates offices across North America (Montréal, Calgary, Vancouver and New York), as well as in key international markets including London, Beijing and Singapore. For more information about TMX Group, visit our website at www.tmx.com. Follow TMX Group on Twitter: @TMXGroup.

SOURCE TMX Group Limited

Posted on

iRhythm Technologies Provides Statement on Medicare Administrative Contractor (MAC) Novitas Recent Rate Publication

SAN FRANCISCO, Jan. 29, 2021 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, commented on the recent publication by Novitas Solutions (“Novitas”) of rates applicable to the Current Procedural Terminology (CPT) codes 93241, 93243, 93245 and 93247.

Following the Centers for Medicare and Medicaid Services (CMS) Calendar Year 2021 Medicare Physician Fee Schedule (MPFS) Final Rule published on December 1, 2020, iRhythm has been coordinating with other industry participants to seek appropriate carrier pricing for CPT codes 93241, 93243, 93245 and 93247. iRhythm submitted a meeting request with Novitas on January 3, 2021. iRhythm anticipates meeting with Novitas but the meeting has not yet been scheduled.

The Company believes that the published rates by Novitas on January 29, 2021, are crosswalked from CPT codes 93224 and 93226, which are existing CPT codes for external continuous electrocardiographic recording up to 48 hours.

The Company is seeking additional information from Novitas and will provide updates as soon as practicable.

About iRhythm Technologies, Inc.

iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These statements include statements regarding CPT coding decisions, the company’s expectations regarding government and third-party payor adoption of CPT coding decisions and the timing thereof and other statements relating to reimbursement coverage. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled “Risk Factors” and elsewhere in our filing made with the Securities and Exchange Commission on the Form 10-Q on November 6, 2020. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. iRhythm disclaims any obligation to update these forward-looking statements.

Investor Relations Contact

Leigh Salvo
(415) 937-5404
[email protected]

Media Contact
Saige Smith  
(262) 289-7065
[email protected]



Posted on

Vertical Capital Income Fund (VCIF) Announces Estimated Distribution Sources

PR Newswire

DALLAS, Jan. 29, 2021 /PRNewswire/ — As previously announced, Vertical Capital Income Fund (NYSE: VCIF) paid a monthly distribution of $0.08 per share to all shareholders of record as of January 19, 2021, pursuant to the Fund’s managed distribution plan (the “Plan”).

As a general matter, the amount of the Fund’s distributable income depends on the aggregate gains and losses realized by the Fund during the entire year. Distributions may consist of net investment income, capital gains and return of capital but the character of these distributions cannot be determined until after the end of the Fund’s fiscal year. However, under the Investment Company Act of 1940, as amended, and the terms of the Plan, the Fund may be required to indicate the source of each distribution to its shareholders. The following table sets forth the estimated sources of the current distribution, and the cumulative distributions paid during the 2021 fiscal year to date from the sources indicated in the table. All amounts are expressed on a per share basis and as a percentage of the distribution amount.

Source

Current

Distribution

Per Share

Breakdown of

Current

Distribution Per

Share (%)

Fiscal YTD

Cumulative

Distributions

Per Share

Breakdown of Fiscal

YTD Cumulative

Distributions Per

Share (%)

Net Investment

Income

$0.029

36.25%

$0.204

42.95%

Net Realized Short-

Term Capital Gains

$0.006

7.50%

$0.006

1.26%

Net Realized Long-

Term Capital Gains

$0.045

56.25%

$0.265

55.79%

Return of Capital

or Other Capital

Source(s)

$0.000

0.00%

$0.000

0.00%

Total Distributions

$0.080

100%

$0.475

100%

 

  1. You should not draw any conclusions about the Fund’s investment performance from the amount of this distribution or from the terms of the Fund’s Distribution Policy.
  2. The amounts and sources of distributions reported in this press release are only estimates and are not being provided for tax reporting purposes.  The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations.  The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.

 

Average annual total return at NAV for the 5-year period ended on December 31, 20201

5.74%

Annualized current distribution rate expressed as a percentage of NAV as of December
31, 20202

7.99%

Cumulative total return at NAV for the fiscal year through December 31, 20203

3.05%

Cumulative fiscal year to date distribution rate as a percentage of NAV as of December
31, 20204

3.29%

 


1

Average annual total return at NAV represents the change in NAV of the Fund, with all distributions reinvested, for the 5-year period ended on December 31, 2020.


2

The annualized current distribution rate is the cumulative distribution rate annualized as a percentage of the Fund’s NAV as of December 31, 2020.


3

Cumulative total return at NAV is the percentage change in the Fund’s NAV for the period from the beginning of its fiscal year to December 31, 2020 including distributions paid and assuming reinvestment of those distributions.


4

Cumulative fiscal year distribution rate for the period from the beginning of its fiscal year to December 31, 2020 measured on the dollar value of distributions in the year-to-date period as a percentage of the Fund’s NAV as of December 31, 2020.

The Plan will be subject to periodic review by the Board, and the Board may amend the terms of the Plan including amending the annual rate of payment or may terminate the Plan at any time without prior notice to the Fund’s shareholders.  The Fund’s distribution rate may be affected by numerous factors, including changes in realized and projected market returns, Fund performance, and other factors.  There can be no assurance that an unanticipated change in market conditions or other unforeseen factors will not result in a change in the Fund’s distribution rate at a future time.  The amendment or termination of the Plan could have an adverse effect on the market price of the Fund’s shares.  The public health crises caused by the COVID-19 outbreak may exacerbate other pre-existing political, social and economic risks to which the Fund is exposed.  The duration of the COVID-19 outbreak and its effects cannot be determined with certainty.  In order to comply with the requirements of Section 19 of the Investment Company Act of 1940, and an exemptive order received by the Fund from the Securities and Exchange Commission, the Fund will provide its shareholders of record on each distribution date with a 19(a) Notice and issue an accompanying press release disclosing the sources of its distribution payment when a distribution includes anything other than net investment income.  This information will be forthcoming later this month.

The amounts and sources of distributions reported in 19(a) Notices are only estimates and are not provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during its full fiscal year and may be subject to changes based on tax regulations. The Fund will send shareholders a Form 1099-DIV for the calendar year that will tell them how to report these distributions for federal income tax purposes. Information on the Fund’s 19(a) Notices, if any, can be found at www.vertical-incomefund.com. The final
determination of the source and tax characteristics of all distributions in 2021 will be made after the end of the year.


Shares of closed-end funds often trade at a discount from their net asset value. The market price of Fund shares may vary from net asset value based on factors affecting the supply and demand for shares, such as Fund distribution rates relative to similar investments, investors’ expectations for future distribution changes, the clarity of the Fund’s investment strategy and future return expectations, and investors’ confidence in the underlying markets in which the Fund invests. Fund shares are subject to investment risk, including possible loss of principal invested. No Fund is a complete investment program and you may lose money investing in a Fund. An investment in the Fund may not be appropriate for all investors. Before investing, prospective investors should consider carefully the Fund’s investment objective, risks, charges and expenses.  For further details, please visit Vertical Capital Income Fund’s website at vertical-incomefund.com.

This release contains forward-looking statements relating to the business and financial outlook of Vertical Capital Income Fund that are based on the Fund’s current expectations, estimates, forecasts and projections and are not guarantees of future performance. There is no assurance that the Fund will achieve its investment objective. Actual results may differ materially from those expressed in these forward-looking statements, and you should not place undue reliance on any such statements. A number of important factors could cause actual results to differ materially from the forward-looking statements contained in this release.

About Vertical Capital Income Fund

Vertical Capital Income Fund is an NYSE listed closed-end fund that primarily invests in residential whole mortgage loans and residential whole loans secured by deeds of trust.  The investment objective of the Fund is to seek income.

About Oakline Advisors, LLC

Oakline Advisors, LLC is the adviser to Vertical Capital Income Fund.  Founded in 2013, Oakline Advisors, LLC is an SEC-registered investment adviser that specializes in the residential whole loan market. It is a wholly owned subsidiary of Dallas, TX-based Behringer.  Since its inception in 1989, Behringer, together with its affiliates, has raised equity of more than $6 billion in assets through public and private fund structures.  For more information about Oakline and Behringer please visit their respective websites at oaklineadvisors.com and behringerinvestments.com. 

Fund shares are identified by CUSIP 92535C104

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/vertical-capital-income-fund-vcif-announces-estimated-distribution-sources-301218263.html

SOURCE Vertical Capital Income Fund

Posted on

Moore Kuehn Encourages ANDA, TSIA, CCX, and PSAC Investors to Contact Law Firm

PR Newswire

NEW YORK, Jan. 29, 2021 /PRNewswire/ — Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.  Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies:


  • Andina Acquisition Corp. III (NASDAQ: ANDA)

Andina Acquisition has agreed to merge with Stryve Foods.  Under the proposed transaction, Andina shareholders will own under 33% of the combined company.


  • TS Innovation Acquisitions Corp. (NASDAQ: TSIA)

TS Innovation has agreed to merge with Latch, Inc.  Under the proposed transaction, shareholders of TS will own only 19% of the combined company.


  • Churchill Capital Corp II (NYSE: CCX)

Churchill Capital has agreed to merge with Software Luxembourg Holding.  Under the proposed transaction, shareholders of Churchill will retain only 65%% of the combined company.


  • Property Solutions Acquisition Corp. (NASDAQ: PSAC)

Property Solutions has agreed to merge with Faraday Future.  Under the proposed transaction, shareholders of Property Solutions will own just 6.8% of the combined company.

Moore Kuehn is investigating whether the Boards of the above companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process. 

Moore Kuehn encourages shareholders who would like to discuss their rights to contact Justin Kuehn, Esq. by email at [email protected] or telephone at (212) 709-8245.  The consultation and case are free with no obligation to you.  Moore Kuehn pays all case costs and does not charge its investor clients.Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

Moore Kuehn is a 5-star Google rated New York City law firm with attorneys representing investors and consumers in litigation involving securities laws, fraud, breaches of fiduciary duties, and other claims.  For additional information about Moore Kuehn, please visit http://www.moorekuehn.com/practice/new-york-securities-litigation/.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:
Moore Kuehn, PLLC
Justin Kuehn, Esq.
30 Wall Street, 8th Floor
New York, New York 10005
[email protected] 
(212) 709-8245

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/moore-kuehn-encourages-anda-tsia-ccx-and-psac-investors-to-contact-law-firm-301218262.html

SOURCE Moore Kuehn, PLLC

Posted on

AM Best Affirms Ratings of Knighthead Annuity

GEORGE TOWN, Cayman Islands, Jan. 29, 2021 (GLOBE NEWSWIRE) — Knighthead Annuity & Life Assurance Company™ announced today that A.M. Best, the world’s oldest and most authoritative insurance rating and information source, has completed its mid-year review of the company. On January 21, 2021, A.M. Best affirmed the financial strength rating of A- (Excellent) and issuer credit rating of a- (Excellent). The outlook for both ratings remains “Stable”.

“We are pleased, but not surprised, that at conclusion of their mid-year review, A.M. Best affirmed the A category ratings for Knighthead Annuity,” stated Gary M. Dombowsky, Chief Executive Officer. “The ratings process represents a comprehensive analysis consisting of a quantitative and qualitative evaluation of balance sheet strength, operating performance, management and business profile. Our direct business clients and distributors, as well as our reinsurance counterparties, benefit from the validation and transparency that comes from an independent rating. We encourage all firms to review our ratings reports available by visiting our web-site at www.knightheadannuity.com,” he added.


About Knighthead Annuity

Knighthead Annuity & Life Assurance Company™ is rated by both Kroll Bond Rating Services and A.M. Best. The Company offers fixed annuities to international clients through regulated institutional distribution partners and reinsurance of fixed liabilities from other insurers.


Contact

Nathan V. Gemmiti: (345) 623-0300 | [email protected]

Knighthead
Annuity
is not licensed to sell products in the United States. It is licensed by the Cayman Islands Monetary Authority. Its
products
are
not
offered
for
sale
to
any
resident
or
citizen
of
the
United
States,
in
the
United
States
or
in
any
other
jurisdiction
where d
istribution
or
use would
be
contrary
to
law
or
regulations. Prospectivepurchasersshouldobtain independentfinancial,legalandtaxadviceto ensuresuitabilityandadherencetoanylocalregulatoryrequirements. For up to date rating information visit www.ambest.com and www.krollbondratings.com.



Posted on

Eight Eclipse Senior Living Communities Earned SeniorAdvisor.com 2021 Best of Senior Living Award

Top Reviews from Residents and Families Showcase Outstanding Care Provided by Eclipse Senior Living Communities to Keep Seniors Feeling Safe, Healthy and Happy

LAKE OSWEGO, Ore., Jan. 29, 2021 (GLOBE NEWSWIRE) — Eclipse Senior Living is proud to announce eight of its communities have been honored as a SeniorAdvisor.com Best of Senior Living 2021 award winner by A Place for Mom, Inc. (APFM), the largest senior living referral service in North America. The best of senior living honor represents the best of the best of in-home care, assisted living, and other senior living providers, determined by the reviews of seniors and their families on SeniorAdvisor.com, the nation’s largest ratings and reviews site for senior care and services. This exclusive designation honors only the top three percent of senior care providers across the United States and Canada. 

The Eclipse Senior Living communities that were recognized are: 

  • Elmcroft of Braeswood in Houston, Texas.  
  • Elmcroft of Carrollwood in Tampa, Fla. 
  • Elmcroft of Chesterfield in Richmond, Va. 
  • Elmcroft of Muncie in Muncie, Ind. 
  • Elmcroft of Pinecrest in Largo, Fla. 
  • Elmcroft of Quintessence in Albuquerque, N.M. 
  • Elmcroft of the Mainland in Texas City, Texas. 
  • Grossmont Gardens in La Mesa, Calif. 

This year has been tough for so many and Eclipse Senior Living has shown its resilience in the face of this challenge. Many of the top reviews shared what kept residents feeling safe, less isolated, and stimulated both mentally and physically. From hallway parades, easily-accessible video calls with family, to having staff just be there to engage with residents and caregivers when they are needed most, Eclipse Senior Living’s communities provided the utmost care. 

“We’re so proud of all our communities across the country and the dedication of all our associates to providing the best care possible during these extraordinary times,” said Kai Hsiao, Eclipse Senior Living CEO. “All of our communities work hard to uphold our mission of enriching the lives of those who live and work with us through excellent care and service. This recognition by SeniorAdvisor.com and A Place for Mom and the users of these platforms is greatly appreciated. We’ll continue to work hard to grow the list of our communities recognized next year.”  

“During a year that challenged all of us, and particularly frontline healthcare workers, senior living communities demonstrated resilience going above and beyond to keep residents safe, healthy, and happy,” said Sue Johansen, Senior Vice President, Community Network, at A Place for Mom. “Of the nearly 45,000 senior living care providers in North America currently listed on SeniorAdvisor.com and hundreds of thousands of reviews, only the top 3% were recognized with this prestigious award, simply by providing the highest level of care that residents and their families deserve.” 

To learn more about the Best of 2021 Senior Living Awards, please visit www.senioradvisor.com/awards/best-assisted-living.

About Eclipse Senior Living 
Eclipse Senior Living is a national manager of distinctive Independent, Assisted Living and Memory Care communities across the United States, including the brands Elmcroft™ and Embark™. The Eclipse Senior Living portfolio includes over 100 communities in more than 25 states. To learn more about Eclipse Senior Living, visit: eclipseseniorliving.com

About A Place for Mom 
A Place for Mom is an online platform connecting families searching for senior care services with a team of experienced advisors providing insight-driven and personalized solutions.  Its mission, as the leader in senior care advisory, is to be a trusted destination for families and our community customers. They are a quickly growing organization with over 500 senior living experts connecting hundreds of thousands of families every year to one of its community customers. For more information, visit www.aplaceformom.com.

About SeniorAdvisor.com 
SeniorAdvisor.com is the leading consumer ratings and reviews site for senior living communities and home-care providers across the U.S. and Canada. The innovative website provides easy access to the information families need when making a senior-care decision, and features more than 240,000 trusted reviews and advice from local residents and their loved ones. For more information, visit www.SeniorAdvisor.com.

Alison Attebery


[email protected]



Posted on

Colfax Schedules Fourth Quarter 2020 Earnings Release and Conference Call

Annapolis Junction, MD, Jan. 29, 2021 (GLOBE NEWSWIRE) — Colfax Corporation (NYSE: CFX), a leading diversified technology company, today announced that it will issue a press release providing financial results for the fourth quarter of 2020 on the morning of Thursday, February 18, 2021. The Company will hold a conference call to discuss these results beginning at 8:00 a.m. Eastern on that day, which will be open to the public by calling +1-877-303-7908 (U.S. callers) and +1-678-373-0875 (International callers) and referencing the conference ID number 3753307 and through webcast via Colfax’s website www.colfaxcorp.com under the “Investors” section.

Colfax’s financial results press release and supplemental information referenced on the call, if any, for the fourth quarter of 2020 will be available under the “Investors” section of Colfax’s website prior to the conference call. A link to a replay of the call will also be available on the Colfax website later that day.

About Colfax Corporation

Colfax Corporation is a leading diversified technology company that provides orthopedic and fabrication technology products and services to customers around the world, principally under the DJO and ESAB brands. Colfax believes that its brands are among the most highly recognized in each of the markets that it serves. The Company uses its Colfax Business System (“CBS”), a comprehensive set of tools, processes and values, to create superior value for customers, shareholders and associates. Colfax’s common stock is traded on the NYSE under the ticker “CFX.”  Additional information about Colfax is available at www.colfaxcorp.com.



Investor Contact:

Mike Macek
Vice President, Finance
Colfax Corporation 
+1 (302) 252-9129
[email protected]

Posted on

Incyte Announces Positive CHMP Opinion for Pemigatinib for the Treatment of Adults With Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma With a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangement

Incyte Announces Positive CHMP Opinion for Pemigatinib for the Treatment of Adults With Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma With a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangement

– If approved, pemigatinib will be the first targeted therapy indicated in the EU for this indication

WILMINGTON, Del.–(BUSINESS WIRE)–
Incyte (Nasdaq:INCY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the conditional marketing authorization of pemigatinib for the treatment of adults with unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that is relapsed or refractory, after at least one line of systemic therapy.

“The positive CHMP opinion is a crucial milestone for patients with cholangiocarcinoma, who often have very limited treatment options due to the difficulty of identifying patients during the early disease stages,” said Peter Langmuir, M.D., Group Vice President, Oncology Targeted Therapeutics, Incyte. “Following the recent FDA approval of pemigatinib (Pemazyre®), we are delighted to be closer to offering the first targeted therapy in Europe to benefit these patients.”

The CHMP opinion is based on data from the FIGHT-202 study evaluating the safety and efficacy of pemigatinib in adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with documented FGF/FGFR status. The CHMP’s opinion to recommend the use of pemigatinib is now being reviewed by the European Commission, which has the authority to grant marketing authorizations for medicinal products in the European Union (EU). If approved, pemigatinib will be the first targeted treatment in the EU indicated for patients with unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement and would be commercialized under the brand name Pemazyre.

Cholangiocarcinoma is a rare cancer that forms in the bile duct. It is classified based on its origin: intrahepatic cholangiocarcinoma (iCCA) occurs in the bile duct inside the liver and extrahepatic cholangiocarcinoma occurs in the bile duct outside the liver. Patients with cholangiocarcinoma are often diagnosed at a late or advanced stage when the prognosis is poor1,2. In Europe, the incidence of cholangiocarcinoma ranges between 6,000 – 8,0003,4. FGFR2 fusions or rearrangements occur almost exclusively in iCCA, where they are observed in 10-16 percent of patients5,6,7.

About FIGHT-202

The FIGHT-202 Phase 2, open-label, multicenter study (NCT02924376) is evaluating the safety and efficacy of pemigatinib – a selective fibroblast growth factor receptor (FGFR) inhibitor – in adult (age ≥ 18 years) patients with previously treated, locally advanced or metastatic cholangiocarcinoma with documented FGF/FGFR status.

Patients were enrolled into one of three cohorts – Cohort A (FGFR2 fusions or rearrangements), Cohort B (other FGF/FGFR genetic alterations) or Cohort C (no FGF/FGFR genetic alterations). All patients received 13.5 mg pemigatinib orally once daily (QD) on a 21-day cycle (two weeks on/one week off) until radiological disease progression or unacceptable toxicity.

The primary endpoint of FIGHT-202 is overall response rate (ORR) in Cohort A, assessed by independent review per RECIST v1.1. Secondary endpoints include ORR; progression free survival (PFS), overall survival (OS), duration of response (DOR), disease control rate (DCR) and safety in all cohorts.

For more information about FIGHT-202, visit https://clinicaltrials.gov/ct2/show/NCT02924376.

About FIGHT

The FIGHT (FIbroblast Growth factor receptor in oncology and Hematology Trials) clinical trial program includes ongoing Phase 2 and 3 studies investigating safety and efficacy of pemigatinib therapy across several FGFR-driven malignancies. Phase 2 monotherapy studies include FIGHT-202, as well as FIGHT-201 investigating pemigatinib in patients with metastatic or surgically unresectable bladder cancer, including with activating FGFR3 mutations or fusions/rearrangements; FIGHT-203 in patients with myeloproliferative neoplasms with activating FGFR1 fusions/rearrangements; FIGHT-207 in patients with previously treated, locally-advanced/metastatic or surgically unresectable solid tumor malignancies harboring activating FGFR mutations or fusions/rearrangements, irrespective of tumor type.

FIGHT-302 is a Phase 3 study investigating pemigatinib as a first-line treatment for patients with cholangiocarcinoma with FGFR2 fusions or rearrangements.

About FGFR and Pemigatinib

Fibroblast growth factor receptors (FGFRs) play an important role in tumor cell proliferation and survival, migration and angiogenesis (the formation of new blood vessels). Activating fusions, rearrangements, translocations and gene amplifications in FGFRs are closely correlated with the development of various cancers.

Pemigatinib is a potent, selective, oral inhibitor of FGFR isoforms 1, 2 and 3 which, in preclinical studies, has demonstrated selective pharmacologic activity against cancer cells with FGFR alterations.

About Incyte

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

Forward Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding whether or when pemigatinib might be approved in the EU for the treatment of, and whether or when pemigatinib might provide a successful treatment option for, patients with unresectable locally advanced or metastatic cholangiocarcinoma, and the FIGHT clinical trial program. These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by European regulatory authorities or other regulatory authorities, including the U.S. FDA; the Company’s dependence on its relationships with its collaboration partners; the efficacy or safety of the Company’s products and the products of the Company’s collaboration partners; the acceptance of the Company’s products and the products of the Company’s collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; greater than expected expenses; expenses relating to litigation or strategic activities; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its Form 10-Q for the quarter ending September 30, 2020. The Company disclaims any intent or obligation to update these forward-looking statements.

__________________

1 Banales JM, et al. Nat Rev Gastroenterol Hepatol. 2016;13:261‒280.

2 Uhlig J, et al. Ann Surg Oncol. 2019;26:1993–2000.

3 Kirstein MM, Vogel A. Visc Med 2016; 32: 395-400.

4 Countries factored include: UK, Germany, France, Spain, Italy, Switzerland, Denmark, Finland, Poland and Austria

5 Graham RP, et al. Hum Pathol. 2014;45:1630‒1638.

6 Ang C. J. Gastroenterol Hepatol. 2015;30:1116‒1122.

7 Ross JS et al. The Oncologist. 2014;19:235–242.

Incyte:

Media

Catalina Loveman

Executive Director, Public Affairs

+1 302 498 6171

[email protected]

Ela Zawislak

Director, Public Affairs

+41 21 343 3113

[email protected]

Investors

Dr. Michael Booth

Division VP, IR & Global Responsibility

+1 302 498 5914

[email protected]

Christine Chiou

Senior Director, Investor Relations

+1 302 274 4773

[email protected]

KEYWORDS: Delaware Europe United States North America

INDUSTRY KEYWORDS: Oncology Health Clinical Trials Research Science Pharmaceutical Biotechnology

MEDIA:

Logo
Logo
Posted on

The Next Green Initiative is Internet Sustainability

Heficed CEO & Founder Vincentas Grinius, introduces IPXO, the world’s first IP marketplace

LONDON, Jan. 29, 2021 (GLOBE NEWSWIRE) — IPXO, formerly known as Heficed’s IP Address Platform, is now the world’s first IP marketplace. According to Vincentas Grinius, CEO of IPXO, “The use of Internet resources has been growing exponentially, reinforcing the need for a more capable cyberspace infrastructure to support the immense surge. Although many complex tech solutions are leading the Internet to a new era, the current network architecture is lagging to progress at the same speed, raising the question if the fall back will force current developments to hit the brakes till it can catch up”.

Business Insider projects there will be over 41 billion IoT devices by the year 2027 – a truly staggering growth in comparison to 2019, when there was about 8 billion. The fast-paced development of the Internet of Things is one of the main triggers, pushing the network to evolve infrastructure-wise. Heavily-reliant on real-time data, IoT needs significant data speeds to utilize its full potential. 

To simplify the solution, it is important to understand that the foundation of the internet is IPv4 addresses. These addresses enable information exchanges and connections between servers and internet enabled devices (phones, tablets, computers, etc.). When devices are retired or migrated to IPv6, IPv4 addresses become dormant (also called “sleeping addresses”).

IPv4 uses a 32-bit address, allowing for 4.3 billion unique addresses. IPv6 uses a 128-bit address, which provides an immensely higher number of unique address combinations. For some massive global organizations, transitioning from majority IPv4 to majority IPv6 is a great solution. However, it is not a great solution for everyone. Because less than 30% of all internet-connected networks promote IPv6 connectivity, organizations transitioning to IPv6 will have to run IPv4 and IPv6 simultaneously which is both slow and expensive.

Some experts are recommending a shared addresses model where a public IPv4 address is assigned to cover several customers simultaneously. Each customer would have a different port range internally to ensure that there was no overlap. While a good idea conceptually, the technical execution is expensive to build and challenging to maintain. It will likely also lead to slowdowns and more moving parts that can fail.

Neither solution takes into account the millions of dormant IPv4 addresses. Grinius believes, “We don’t need added layers of complexity that will add cost and slowdown transfers of data. What we do need is a way to incentivize ISPs (or other businesses) who are sitting on tens of thousands or hundreds of thousands of unassigned IPv4 addresses to bring those addresses to market for other organizations.” This is where IPXO was conceived says Grinius, “We needed a global platform where IPv4 addresses could be securely leased and monetized.

About IPXO

IPXO, formerly known as Heficed’s IP Address Market, is an IP resource management platform, which enables to monetize unused IP addresses via lease. Reportedly having outgrown its current position as part of Heficed’s framework, it will continue to grow and improve as a separate business entity, with the full switch predicted at the beginning of 2021. IPXO will be equipped with advanced features such as reputation monitoring, delegated RPKI, WHOIS, Geo object management, BGP announcement control, and open API.

A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/06ab1589-cac2-4939-a8c5-3b49832f5883

Media Contact:
Eric Reed
[email protected]
(614)896-0874